Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Strober B, Paul C, Blauvelt A, Thaçi D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K. Strober B, et al. Among authors: eyerich k. J Am Acad Dermatol. 2023 Sep;89(3):486-495. doi: 10.1016/j.jaad.2023.04.063. Epub 2023 May 12. J Am Acad Dermatol. 2023. PMID: 37182701 Free article. Clinical Trial.
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Reich K, et al. Among authors: eyerich k. Immunotherapy. 2023 Sep;15(13):975-980. doi: 10.2217/imt-2022-0306. Epub 2023 May 31. Immunotherapy. 2023. PMID: 37254941 Review.
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: eyerich k. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases.
Seremet T, Di Domizio J, Girardin A, Yatim A, Jenelten R, Messina F, Saidoune F, Schlapbach C, Bogiatzi S, Minisini F, Garzorz-Stark N, Leuenberger M, Wüthrich H, Vernez M, Hohl D, Eyerich S, Eyerich K, Guenova E, Paul C, Gottardo R, Conrad C, Gilliet M. Seremet T, et al. Among authors: eyerich k. Nat Commun. 2024 Dec 18;15(1):10688. doi: 10.1038/s41467-024-54559-6. Nat Commun. 2024. PMID: 39695162 Free PMC article.
Experience of patients and healthcare practitioners with interdisciplinary care in immune-mediated inflammatory diseases with skin manifestations: A systematic scoping review.
Van den Steen E, De Cock D, Lambert JLW, Reynaert V, Eyerich K, Marinović B, Gutermuth J. Van den Steen E, et al. Among authors: eyerich k. J Eur Acad Dermatol Venereol. 2024 Dec 7. doi: 10.1111/jdv.20449. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39644149 Review.
Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database.
Mongin D, Matucci-Cerinic M, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR collaborators. Mongin D, et al. Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25469. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39542851 Free article.
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.
Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM, Siegert E, Henes J, Zanatta E, Riccieri V, Truchetet ME, Oksel F, Li M, Kucharz EJ, Eyerich K, Del Galdo F, Vonk MC, Vold AH, Gabrielli A, Distler O; EUSTAR collaborators. Wyss A, et al. Among authors: eyerich k. Arthritis Res Ther. 2024 Oct 31;26(1):187. doi: 10.1186/s13075-024-03418-2. Arthritis Res Ther. 2024. PMID: 39482761 Free PMC article.
239 results